Key Takeaways
- INR3,000 crores milestone crossed: FY26 net income hit a record high, with gross margin improving to 56.7% and EBITDA margin to 20.4%, driven by mix, operating leverage, and softer raw material costs in H2.
- North America is the growth engine: Revenue more than doubled over four years to INR1,533 crores, while the UK rebounded to an all-time quarterly high in Q4 and Australia entered branded prescription generics.
- Raw material inflation is the near-term risk: Petroleum-linked ingredients are up 20-30% on geopolitical disruption, but management is sitting on 5-6 months of inventory and expects a sharp correction if the conflict ends.
- M&A pipeline is live, with a conservative hand: Two targets are under dialogue, one in due diligence; management is optimistic for a 2027 close but insists on value-accretive, non-frothy valuations.
- What to watch next quarter: Whether raw material costs correct or force contract renegotiations, the pace of Teva facility ramp-up toward that 40-50% growth potential, and any M&A announcement.
Revenue Growth & Geographic Mix
- North America dominance: Fastest-growing market, scaling from INR635 crores to INR1,533 crores in four years, demonstrating the operating model's scalability and customer relationship depth.
- UK recovery in Q4: FY26 revenue was marginally impacted by early-year pricing pressure, but Q4 hit an all-time quarterly high on multiple new product launches and improved order flow.
- Australia prescription entry: Through Nova Pharma, launched 11 branded generic products, expanding beyond the deep OTC base; management has a road map to reach $100 million in Australia within three years, currently at the halfway mark.
- New market entries: Expanded international footprint into Germany, Canada, and Ireland; Europe revenue expected within this year, possibly second half, while Canada approvals should trickle in toward the latter part of FY27.
- Geographic margin profile: The U.S. is very competitive with significant pricing pressure; Europe is relatively better on margins; UK performance depends on product basket mix; margins are quite evenly distributed across geographies overall.
- 3-5 year mix outlook: The U.S. will always be a growth driver, but Europe is getting significant weightage; the UK is also growing nicely; new geographies coming into play are Europe and Canada.
Mark Saldanha: "But I do believe INR3,000 crores is just a tip of the iceberg and we have a lot of potential of growth based on our strategy that we are executing as on today."
Margin Performance & Cost Headwinds
- FY26 profitability: Gross margin improved to 56.7%, EBITDA margin to 20.4%; Q4 margin was particularly strong at 22.8%, driven by better product mix, operating leverage, softened raw material cost during the second half, and continued execution efficiencies.
- Raw material inflation entering FY27: Petroleum-related ingredients are up 20% to 30% due to geopolitical and supply chain disruption; management expects inflationary pressure on raw material costs during Q1 FY27.
- Inventory buffer: The company is sitting on 5-6 months of inventory, a conscious decision made last year to go heavy on both finished product and raw materials ahead of tariff uncertainties; this inventory is now being depleted rather than buying at higher prices.
- Currency offset: Foreign currencies have appreciated, providing leverage to absorb some of the cost rise; the overall dollar benefit on the finished product and shipping value chain is much higher than the import cost increase on actives alone.
- Logistics impact: Around 2% and creeping up, but nothing alarming; if the situation stops, freight costs will return to historic lows; current impact is much lower than the Red Sea crisis.
- Contract renegotiation stance: Renegotiating with end customers is always an option, but management prefers to wait and watch given the lack of clarity; if the conflict ends, the overall market will correct dramatically.
Mark Saldanha: "But because there is no clarity, we would like to wait and watch because if tomorrow, things do correct, the overall market will correct dramatically. And the last thing we need is to press a panic today because we are sitting on inventory of a lot of products."
Teva Facility & Capacity
- Utilization and runway: The Teva facility is at very close to 50% utilization, with significant remaining capacity; management sees potential for 40% to 50% growth from that asset and is working toward it.
- Capex within the facility: Some capex is planned to launch different dosage forms not already present, aligned with pipeline product requirements.
- Broader capacity planning: Spare capacity still exists across operations; expansion through land banks or acquiring new plants is being planned for when the time is right; there is no land bank outside Goa presently.
Mark Saldanha: "We still have a potential of maybe 40% to 50% of growth coming from there and we are working towards that."
Pipeline & R&D
- UK filing ambition: Intend to file over 200 products in the UK market over the next four years, creating strong medium-term visibility.
- US pipeline expansion: The 2026-27 pipeline is increasing by about 50-odd products; other geographies have much larger pipelines; the company targets niche products based on market requirements over a 3- to 5-year horizon.
- Approval timelines: Products filed today will see results only at the end of 2027 or early 2028, as it takes about a year to get approved.
- R&D spending: Plan to keep R&D at 3% of revenue.
M&A & Capital Allocation
- Active dialogue: Management is in discussions with two targets; one is currently undergoing due diligence, the other has not started yet; optimistic that 2027 will see some M&A transactions.
- Conservative valuation discipline: Management is explicit about avoiding high-ticket deals and prioritizing return on investment and shareholder value creation.
- Free cash flow: Delivered INR328 crores of free cash flow during FY26 as the major capex cycle completed; cash generation is improving steadily.
- Dividend: Board recommended a final dividend of INR0.90 per equity share, a 90% payout on face value for FY26.
- Australia stake: No call option exists to increase the 60% stake in the Australia/New Zealand entity; management believes they can grow more as partners.
Mark Saldanha: "But for us, we've been always very conservative to make sure that whatever we acquire is value, basically return on investment and creates value for the shareholders. So we are very conservative in the valuation. We don't go for some high-ticket deals and throw money at it."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | INR4,000 crores | Next 2 years |
| Revenue doubling | Double revenue from current levels | Next 3 to 5 years |
| FY27 top-line growth | 15% to 20% (conservative) | FY27 |
| FY27 EBITDA margin | In the range of 20% to 21% | FY27 |
| Australia milestone | Reach $100 million in revenue | Within 3 years |
| UK product filings | File over 200 products | Next 4 years |
| Teva facility growth | 40% to 50% growth potential from the facility | Undated (working toward it) |
| M&A transaction | At least one deal closed | 2027 (optimistic) |
| Europe revenue contribution | Some results from Europe entry | Second half of FY27 |
| Canada revenue contribution | Small revenue to trickle in | Latter part of FY27 |
| R&D spending | Maintain at 3% of revenue | Ongoing |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Operating revenue | ₹856 cr, +20.8% YoY |
| North America revenue | ₹406 cr, +23.6% YoY |
| UK and EU formulation revenue | ₹308 cr, +12.3% YoY, highest ever quarterly revenue |
| Australia and New Zealand revenue | ₹123 cr, +61.3% YoY |
| Rest of world revenue | ₹19 cr |
| Gross profit | ₹465 cr, +21.5% YoY |
| Gross margin | 54.4%, expansion of 27 bps YoY |
| EBITDA | ₹195 cr, +54% YoY |
| EBITDA margin | 22.8%, expanded 491 bps YoY |
| Profit after tax | ₹149 cr, +64.3% YoY |
| EPS | ₹3.3 |
| FY26 operating revenue | ₹2,951 cr, +12.5% YoY |
| FY26 gross margin | 56.7%, expanded 32 bps YoY |
| FY26 EBITDA margin | 20.4% |
| FY26 PAT | ₹420 cr |
| FY26 EPS | ₹9.2 |
| FY26 free cash flow | ₹328 cr |
| Working capital | 138 days |
| R&D spend | ₹89 cr in FY26, 3% of consolidated revenue |
| Cash and cash equivalents | ₹990 cr as of March 31, 2026 |
| Dividend | ₹0.90 per equity share, 90% payout on face value for FY26 |
| North America FY26 revenue | ₹1,533 cr, +24% YoY, 52% of total operating revenue |
| UK and EU FY26 revenue | ₹1,015 cr, 34.4% of total operating revenue |
| Australia and New Zealand FY26 revenue | ₹303 cr, 10.3% of total operating revenue |
| North America SKUs launched in FY26 | 112 SKUs, 51 additional products in pipeline |
| UK product pipeline | 18 new approvals, 30 under review, 24 awaiting approvals; over 200 filings planned over next 4 years |
| Australia branded generic launches | 11 branded generic products launched through Nova Pharma |
| Teva facility utilization | Very close to 50% of capacity |
| Total operational capacity utilization | 50% to 55% across all 3 facilities, 1,300 cr to 1,400 cr units |
| Raw material price escalation | Over 20% to 30% on petroleum-related raw materials |
| Logistics cost impact | Around 2% |
| FY27 revenue growth guidance | 15% to 20% conservatively |
| FY27 EBITDA margin guidance | 20% to 21%, same range |
| Revenue target | ₹4,000 cr in the next 2 years |
| Australia and New Zealand revenue target | $100 million, currently at halfway mark |
| Marksans stake in Australia and New Zealand entity | 60% |